scholarly journals Correction: O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma

2020 ◽  
Vol 56 (29) ◽  
pp. 4130-4131
Author(s):  
Chengfeng Bai ◽  
Rongfang Xue ◽  
Jianbing Wu ◽  
Tian Lv ◽  
Xiaojun Luo ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Donors ◽  
New Class

Correction for ‘O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma’ by Chengfeng Bai et al., Chem. Commun., 2017, 53, 5059–5062.

scholarly journals Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis

2020 ◽  
Vol 21 (8) ◽  
pp. 2703 ◽  
Author(s):  
Tommaso Gori
Keyword(s):  
Nitric Oxide ◽  
Endothelial Dysfunction ◽  
Plaque Rupture ◽  
Nitric Oxide Donors ◽  
New Class ◽  
Amyl Nitrite ◽  
Treatment And Prevention ◽  
The Subject ◽  
Prevention Of Atherosclerosis ◽  
Nitric Oxide Pathway

Amyl nitrite was introduced in 1867 as the first molecule of a new class of agents for the treatment of angina pectoris. In the following 150 years, the nitric oxide pathway has been the subject of a number of pharmacological approaches, particularly since when this elusive mediator was identified as one of the most important modulators of vascular homeostasis beyond vasomotion, including platelet function, inflammation, and atherogenesis. While having potent antianginal and antiischemic properties, however, nitric oxide donors are also not devoid of side effects, including the induction of tolerance, and, as shown in the last decade, of oxidative stress and endothelial dysfunction. In turn, endothelial dysfunction is itself felt to be involved in all stages of atherogenesis, from the development of fatty streaks to plaque rupture and thrombosis. In the present review, we summarize the agents that act on the nitric oxide pathway, with a particular focus on their potentially beneficial antiatherosclerotic and unwanted pro-atherosclerotic effects.

A new class of nitric oxide donors

2016 ◽  
Vol 86 (3) ◽  
pp. 158-163 ◽  
Author(s):  
S. M. Aldoshin ◽  
N. A. Sanina ◽  
M. I. Davydov ◽  
E. I. Chazov
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Donors ◽  
New Class

O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma

2017 ◽  
Vol 53 (36) ◽  
pp. 5059-5062 ◽  
Author(s):  
Chengfeng Bai ◽  
Rongfang Xue ◽  
Jianbing Wu ◽  
Tian Lv ◽  
Xiaojun Luo ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Donor ◽  
Nitric Oxide Donors ◽  
New Class

3c, a new nitric oxide donor activatable by GSH/GSTπ, exhibits both anti-proliferative and anti-metastatic activities against melanoma.

scholarly journals The Application of Nitric Oxide for Ocular Hypertension Treatment

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7306
Author(s):  
Binze Han ◽  
Maomao Song ◽  
Liping Li ◽  
Xinghuai Sun ◽  
Yuan Lei
Keyword(s):  
Nitric Oxide ◽  
Ocular Hypertension ◽  
Nitric Oxide Donors ◽  
Hypertension Treatment ◽  
Aqueous Humor Outflow ◽  
New Class ◽  
Pubmed Database ◽  
Main Pathway ◽  
Outflow Pathway ◽  
Outflow System

Despite of various therapeutic methods for treating ocular hypertension and glaucoma, it still remains the leading cause of irreversible blindness. Intraocular pressure (IOP) lowering is the most effective way to slow disease progression and prevent blindness. Among the ocular hypotensive drugs currently in use, only a couple act on the conventional outflow system, which is the main pathway for aqueous humor outflow and the major lesion site resulting in ocular hypertension. Nitric oxide (NO) is a commendable new class of glaucoma drugs that acts on the conventional outflow pathway. An increasing number of nitric oxide donors have been developed for glaucoma and ocular hypertension treatment. Here, we will review how NO lowers IOP and the types of nitric oxide donors that have been developed. And a brief analysis of the advantages and challenges associated with the application will be made. The literature used in this review is based on Pubmed database search using ‘nitric oxide’ and ‘glaucoma’ as key words.

Sulfhydryl-Containing Nitrate Esters: A New Class of Nitric Oxide Donors

1995 ◽  
Vol 13 (3) ◽  
pp. 275-288 ◽  
Author(s):  
Georg Kojda ◽  
Martin Feelisch ◽  
Eike Noack
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Donors ◽  
Nitrate Esters ◽  
New Class

Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis

2010 ◽  
pp. 459-477 ◽  
Author(s):  
Benjamin Bonavida ◽  
Stavroula Baritaki ◽  
Sara Huerta-Yepez ◽  
Mario I. Vega ◽  
Ali R. Jazirehi ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cancer Therapeutics ◽  
Nitric Oxide Donors ◽  
New Class ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document